T. Rowe Price Associates
OLMA icon

T. Rowe Price Associates’s Olema Pharmaceuticals OLMA Stock Holding History

T. Rowe Price Associates’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.3M Sell
826,569
-356,267
-30% -$4.77M ﹤0.01% 1321
2026
Q1 		$17.6M Buy
1,182,836
+86,801
+8% +$1.93M ﹤0.01% 1079
2025
Q4 		$27.4M Buy
1,096,035
+1,064,254
+3,349% +$18.9M ﹤0.01% 981
2025
Q3 		$312K Buy
31,781
+1,920
+6% +$11.5K ﹤0.01% 2588
2025
Q2 		$128K Buy
29,861
+12,325
+70% +$55K ﹤0.01% 2843
2025
Q1 		$66K Sell
17,536
-8,576
-33% -$43.1K ﹤0.01% 2894
2024
Q4 		$153K Sell
26,112
-5,346
-17% -$53.4K ﹤0.01% 2763
2024
Q3 		$376K Buy
31,458
+216
+0.7% +$2.76K ﹤0.01% 2376
2024
Q2 		$339K Buy
31,242
+4,991
+19% +$54.1K ﹤0.01% 2368
2024
Q1 		$298K Buy
26,251
+1,486
+6% +$19.2K ﹤0.01% 2436
2023
Q4 		$348K Sell
24,765
-14,081
-36% -$189K ﹤0.01% 2333
2023
Q3 		$480K Sell
38,846
-22,007
-36% -$224K ﹤0.01% 2122
2023
Q2 		$550K Buy
60,853
+2,553
+4% +$15.4K ﹤0.01% 2085
2023
Q1 		$203K Sell
58,300
-10,200
-15% -$41.6K ﹤0.01% 2521
2022
Q4 		$168K Hold
68,500
– – ﹤0.01% 2586
2022
Q3 		$190K Hold
68,500
– – ﹤0.01% 2561
2022
Q2 		$279K Sell
68,500
-2,372
-3% -$7.52K ﹤0.01% 2474
2022
Q1 		$302K Buy
70,872
+700
+1% +$3.86K ﹤0.01% 2545
2021
Q4 		$657K Buy
+70,172
New +$1.45M ﹤0.01% 2257
2021
Q3 		– Sell
-8,623
Closed -$241K – 2975
2021
Q2 		$241K Buy
8,623
+173
+2% +$4.92K ﹤0.01% 2660
2021
Q1 		$280K Buy
+8,450
New +$362K ﹤0.01% 2588

Other funds holding OLMA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

T. Rowe Price Associates's OLMA Position: Q2 2026 in Review

T. Rowe Price Associates reduced its Olema Pharmaceuticals (OLMA) stake by 30% in Q2 2026, selling an estimated $4.77M and leaving 826,569 shares worth $10.3M. The position accounts for ﹤0.01% of the portfolio, ranked #1321.

T. Rowe Price Associates first reported a position in OLMA in Q1 2021 and has held it in 21 quarters since. The position peaked at $27.4M in Q4 2025. 185 funds tracked by Wall St. Rank hold OLMA as of Q2 2026.

  • T. Rowe Price Associates held 826,569 shares of Olema Pharmaceuticals worth $10.3M as of Q2 2026.
  • T. Rowe Price Associates sold 356,267 Olema Pharmaceuticals shares in Q2 2026, an estimated $4.77M.
  • Olema Pharmaceuticals made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #1321 holding.
  • T. Rowe Price Associates first reported a position in Olema Pharmaceuticals in Q1 2021 and has held it in 21 quarters since.
  • T. Rowe Price Associates's Olema Pharmaceuticals position peaked at $27.4M in Q4 2025.
  • 185 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.